SLC25A17

Across TCGA pan-cancer cohorts, SLC25A17 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC25A17 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC25A17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC25A17 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where SLC25A17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.276	1.000	.011	4	view →
HNSC	DFS	Tertile	III,IV	0.749	0.484	.026	3	view →
PDAC	OS	Median	II,III,IV	1.000	0.929	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC25A17–LUAD (DFS)

Open the LUAD breakdown →